H.C. Wainwright analyst Yi Chen lowered the firm’s price target on EyePoint to $33 from $35 and keeps a Buy rating on the shares. Assuming 48.9M shares outstanding at the end of 2024, this yields a price objective of $33, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EYPT:
- Insider Trading: EyePoint Stock (NASDAQ:EYPT) Up on Major Insider Buy
- EyePoint announces first patient dosed in Phase 2 VERONA trial
- EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 2 VERONA Clinical Trial of EYP-1901 for the Treatment of Diabetic Macular Edema
- Short Report: Bearish position in Carvana nudges higher as shares slip
- EyePoint Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference